These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers. McCarthy JS; Baker M; O'Rourke P; Marquart L; Griffin P; Hooft van Huijsduijnen R; Möhrle JJ J Antimicrob Chemother; 2016 Sep; 71(9):2620-7. PubMed ID: 27272721 [TBL] [Abstract][Full Text] [Related]
10. Activity of Ivermectin and Its Metabolites against Asexual Blood Stage Plasmodium falciparum and Its Interactions with Antimalarial Drugs. Yipsirimetee A; Tipthara P; Hanboonkunupakarn B; Tripura R; Lek D; Kümpornsin K; Lee MCS; Sattabongkot J; Dondorp AM; White NJ; Kobylinski KC; Tarning J; Chotivanich K Antimicrob Agents Chemother; 2023 Jul; 67(7):e0173022. PubMed ID: 37338381 [TBL] [Abstract][Full Text] [Related]
11. Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Held J; Supan C; Salazar CL; Tinto H; Bonkian LN; Nahum A; Moulero B; Sié A; Coulibaly B; Sirima SB; Siribie M; Otsyula N; Otieno L; Abdallah AM; Kimutai R; Bouyou-Akotet M; Kombila M; Koiwai K; Cantalloube C; Din-Bell C; Djeriou E; Waitumbi J; Mordmüller B; Ter-Minassian D; Lell B; Kremsner PG Lancet Infect Dis; 2015 Dec; 15(12):1409-19. PubMed ID: 26342427 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria. Adoke Y; Zoleko-Manego R; Ouoba S; Tiono AB; Kaguthi G; Bonzela JE; Duong TT; Nahum A; Bouyou-Akotet M; Ogutu B; Ouedraogo A; Macintyre F; Jessel A; Laurijssens B; Cherkaoui-Rbati MH; Cantalloube C; Marrast AC; Bejuit R; White D; Wells TNC; Wartha F; Leroy D; Kibuuka A; Mombo-Ngoma G; Ouattara D; Mugenya I; Phuc BQ; Bohissou F; Mawili-Mboumba DP; Olewe F; Soulama I; Tinto H; Malar J; 2021 May; 20(1):222. PubMed ID: 34011358 [TBL] [Abstract][Full Text] [Related]
13. A randomized feasibility trial comparing four antimalarial drug regimens to induce Reuling IJ; van de Schans LA; Coffeng LE; Lanke K; Meerstein-Kessel L; Graumans W; van Gemert GJ; Teelen K; Siebelink-Stoter R; van de Vegte-Bolmer M; de Mast Q; van der Ven AJ; Ivinson K; Hermsen CC; de Vlas S; Bradley J; Collins KA; Ockenhouse CF; McCarthy J; Sauerwein RW; Bousema T Elife; 2018 Feb; 7():. PubMed ID: 29482720 [TBL] [Abstract][Full Text] [Related]
14. Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum. Barnes KI; White NJ Acta Trop; 2005 Jun; 94(3):230-40. PubMed ID: 15878154 [TBL] [Abstract][Full Text] [Related]
15. Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor. Rottmann M; Jonat B; Gumpp C; Dhingra SK; Giddins MJ; Yin X; Badolo L; Greco B; Fidock DA; Oeuvray C; Spangenberg T Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041711 [TBL] [Abstract][Full Text] [Related]
16. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. Koita OA; Sangaré L; Miller HD; Sissako A; Coulibaly M; Thompson TA; Fongoro S; Diarra Y; Ba M; Maiga A; Diallo B; Mushatt DM; Mather FJ; Shaffer JG; Anwar AH; Krogstad DJ Lancet Infect Dis; 2017 Dec; 17(12):1266-1275. PubMed ID: 28916443 [TBL] [Abstract][Full Text] [Related]
17. Integrating Pharmacokinetic-Pharmacodynamic Modeling and Physiologically Based Pharmacokinetic Modeling to Optimize Human Dose Predictions for Plasmodium falciparum Malaria: a Chloroquine Case Study. Redhi D; Mulubwa M; Gibhard L; Chibale K Antimicrob Agents Chemother; 2023 May; 67(5):e0134522. PubMed ID: 37010410 [TBL] [Abstract][Full Text] [Related]
18. Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Zaloumis S; Humberstone A; Charman SA; Price RN; Moehrle J; Gamo-Benito J; McCaw J; Jamsen KM; Smith K; Simpson JA Malar J; 2012 Aug; 11():303. PubMed ID: 22931058 [TBL] [Abstract][Full Text] [Related]
19. Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria. Hien TT; White NJ; Thuy-Nhien NT; Hoa NT; Thuan PD; Tarning J; Nosten F; Magnusson B; Jain JP; Hamed K Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872070 [TBL] [Abstract][Full Text] [Related]
20. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. McCarthy JS; Rückle T; Djeriou E; Cantalloube C; Ter-Minassian D; Baker M; O'Rourke P; Griffin P; Marquart L; Hooft van Huijsduijnen R; Möhrle JJ Malar J; 2016 Sep; 15(1):469. PubMed ID: 27624471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]